ClinicalTrials.gg
CompletedNCT05952089Updated Apr 4, 2024

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

A Phase 1 interventional study of Danicamtiv and Midazolam in Heart Failure With Reduced Ejection Fraction, sponsored by Bristol-Myers Squibb. Completed at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Heart Failure by Bristol-Myers Squibb — 1 open to participants now, 2 under way, none of them phase 3. Heart Failure · Bristol-Myers Squibb.

Enrollment
19th of 20
13 · median 54
Started
2023
with 1 other
Phase 1
10 of 28
none open now
Registered
27th of 28
by date

Among the 28 studies in Heart Failure by Bristol-Myers Squibb, this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2023, is one of 10 in phase 1, and was the 27th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 28 studies in Heart Failure by Bristol-Myers Squibb is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Heart Failure by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Browse trials for

Keywords

  • HFrEF
  • Danicamtiv
  • BMS-986434
  • MYK-491
  • Midazolam
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory participants with stable HFrEF due to any etiology.
  • (BMI) of 18.0 kilogram per square meter (kg/m2) to 35.0 kg/m2 inclusive.
  • Documented (LVEF) 15% to 45% (on 2 occasions), including at least once during Screening and confirmed by the Echo Core Laboratory (the absolute difference between the 2 LVEF values qualifying the participant should be \< 12%).
  • Participant receiving chronic medication for the treatment of heart failure reflecting current guidelines, including at least one of the following, unless not tolerated or :β-blocker, angiotensin converting enzyme inhibitor, angiotensin receptor blocker, or angiotensin receptor neprilysin inhibitor. Such treatments should have been given at stable doses for at least ≥ 2 weeks prior to screening with no plan to modify treatments during the study.
  • Sinus rhythm or stable atrial or ventricular pacing or persistent atrial fibrillation that is adequately rate-controlled to allow pharmacodynamic (PD) assessments by Transthoracic echocardiogram (TTE). NOTE: Participants with implanted cardioverter defibrillator (ICD), pacing, or cardiac resynchronization therapy are eligible provided device programming is unchanged starting 2 months prior to and throughout the dosing period.
  • Adequate acoustic windows, determined by the Echo Core Laboratory, to enable accurate TTE assessments.

Exclusion criteria

Exclusion Criteria:

  • Presence of disqualifying cardiac rhythms that would preclude echocardiographic assessments, as determined by the Investigator, including: (a) rapid, inadequately rate controlled atrial fibrillation or (b) frequent premature ventricular contractions that might interfere with reliable echocardiographic measurements of left ventricular function.
  • History of bronchospasm, or history of respiratory depression or arrest, airway obstruction, oxygen desaturation, or apnea.
  • History of allergy to midazolam, other benzodiazepines, danicamtiv, related compounds, or in the formulations.
  • Severe renal insufficiency (defined as current estimated [eGFR] \< 30 mL/min/1.73 m2 by simplified Modification of Diet in Renal Disease equation [sMDRD].
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Danicamtiv + Midazolam

    Drug: Danicamtiv · Drug: Midazolam

Interventions

  • Specified dose on specified days

    Also known as: BMS-986434, MYK-491

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to Day 12

  2. Area under the plasma concentration time curve from time zero extrapolated to infinite time (AUC[INF])

    Time frame: Up to Day 12

  3. Area under the plasma concentration time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])

    Time frame: Up to Day 12

Secondary outcomes

  1. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to Day 12

  2. Terminal elimination half-life (T-HALF)

    Time frame: Up to Day 12

  3. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to Day 12

  4. Number of participants with vital sign abnormalities

    Time frame: Up to Day 12

  5. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 12

  6. Number of participants with physical examination abnormalities

    Time frame: Up to Day 12

  7. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Day 11

07

Study locations

5 sites
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Jacksonville Center For Clinical Research
    Jacksonville, Florida 32216, United States
  • Research Integrity LLC
    Owensboro, Kentucky 42303, United States
  • Sinai Hospital Of Baltimore
    Baltimore, Maryland 21215, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Mar 2024, 6 months.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 19, 2023
StartActual
Aug 17, 2023
Primary completionActual
Mar 15, 2024
CompletionActual
Mar 19, 2024
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05952089
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Aug 17, 2023
Primary completion
Mar 15, 2024
Completion
Mar 19, 2024
Last update
Apr 4, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danicamtiv

Start the discussion